← Back to Search

Gene Editing Therapy

CRD-TMH-001 for Duchenne Muscular Dystrophy

Phase 1
Waitlist Available
Led By Brenda Wong, MD
Research Sponsored by Cure Rare Disease, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Summary

This trial is testing a new treatment that uses advanced technology to fix faulty genes in patients with a rare form of Duchenne muscular dystrophy. The goal is to see if this treatment is safe and effective over time, with long-term follow-up. The treatment works by directly changing the DNA to correct the genetic problem causing the disease. Exon skipping therapy, a method to correct genetic mutations in Duchenne muscular dystrophy, has been in development for many years and has shown promise.

Eligible Conditions
  • Duchenne Muscular Dystrophy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
To assess the safety of CRD-TMH-001

Trial Design

1Treatment groups
Experimental Treatment
Group I: Single patientExperimental Treatment1 Intervention
Single dose of CRD-TMH-001 administered by IV

Find a Location

Who is running the clinical trial?

Cure Rare Disease, IncLead Sponsor
University of Massachusetts, WorcesterOTHER
356 Previous Clinical Trials
992,214 Total Patients Enrolled
Brenda Wong, MDPrincipal InvestigatorUMass Chan Medical School
1 Previous Clinical Trials
22 Total Patients Enrolled
~0 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top